FDA delays Kadmon’s priority review as apparent clampdown continues

Kadmon Holdings just lost their priority review.

The immunology biotech announced Wednesday that the FDA has pushed back the decision date for their graft-versus-host disease drug belumosudil by three months, after the agency requested additional information from the drugmaker. That will effectively turn their 6-month priority review into a 9-month one, just below the FDA’s standard decision-making deadline.